PD lecture Atnc

Parkinson’s disease AskTheNeurologist.Com Author Anon

Essay on the shaking palsy James Parkinson 1817 “ involuntary tremulous motion,with lessened muscular power, in part not in action and even when supported ;with a propensity to bend the trunk forward, and to pass from a walking to a running pace , the senses and intellect being uninjured”

Pathology Loss of pigmented cells in substantia nigra Intracellular cytoplasmic inclusion bodies ( Lewy bodies )

Parkinson disease is characterised by loss of Dopaminergic cells in the substantia nigra leading to abnormal activity in the basal ganglia as a whole This leads to - A decrease in the activity of the direct GABAergic pathway - An increase in the activity of the indirect GABAergic pathway

Uptake of radio-labelled L-Dopa in striatum of normal compared to PD brain

Clinical Features T R A P Tremor Rigidity Akinesia / Bradykinesia Postural instability

Micrographia = manifestation of bradykinesia

Overview of drug treatment
L-Dopa ( bypass rate limiting stem of Dopamine synthesis)
Dopamine agonists ( direct effect on striatum )
COMT inhibitors ( less peripheral inactivation of L-Dopa )
Selegeline ( MAO b ) inhibitor ? Neuroprotective
Muscarinic antagonists ( act on striatal interneurons)
Amantadine ( mechanism unclear ? Dopamine release )

Treatment strategies
The conservative approach
The neuroprotective approach
The symptomatic approach

Conservative approach
Avoid all drugs until symptoms are troublesome
When symptoms become troublesome start amantadine and an anticholinergic
When symptoms become disabling introduce L-Dopa or agonists at minimal doses

Neuroprotective approach
All newly diagnosed cases should be started on Selegeline
When symptoms become disabling add dopaminergic drugs

Symptomatic approach At diagnosis treatment immediately started with dopaminergic drugs Treatment continually modified in order to maintain maximum function for the maximum amount of time

Clinical fluctuations in PD Very difficult to treat Sustained release preparations On-Off phenomenon Increase dose of L-Dopa Increase dose frequency Give before meals “ Off ” periods Ensure L-Dopa not given with protein. Give antacids Delayed onset of response Decrease between dose interval Sustained release L-Dopa Add DA agonist Increase dose Add COMT inhibitor Wearing-off of L-Dopa effect Management Condition

Dyskinesias in PD Clonazepam Decrease L-Dopa Myoclonus Decrease each dose of L-Dopa Add Dopamine agonist Add amantadine Peak-dose dyskinesia Management Type

Psychosis in PD Increased incidence in - Elderly - Pre-existing psychiatric conditions Should only use atypical antipsychotic medications….in particular CLOZAPINE - needs monitoring of white cell count QUETIAPINE - no monitoring necessary - now possibly drug of choice

The End AskTheNeurologist.Com Author Anon

PD lecture Atnc

by Richard Brown on May 26, 2007

Accessibility

Categories

Tags

Upload Details

Usage Rights

2 Embeds 185

Statistics

PD lecture Atnc — Presentation Transcript

http://www.asktheneurologist.com	178
http://www.slideshare.net	7